{"DataElement":{"publicId":"7584416","version":"1","preferredName":"Investigational CAR T-Lymphocyte Agent Type Other","preferredDefinition":"In the process of being studied; experimental._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Something distinguishable as an identifiable class based on common qualities._free text field to describe other investigational chimeric antigen receptor t-lymphocyte treatment type.","longName":"INV_CART_PROD_TYP_OTH","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7580676","version":"1","preferredName":"Investigational CAR T-Lymphocyte Agent Type","preferredDefinition":"In the process of being studied; experimental._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Something distinguishable as an identifiable class based on common qualities.","longName":"7580674v1.0:2223243v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7580674","version":"1","preferredName":"Investigational Chimeric Antigen Receptor T-Lymphocyte Agent","preferredDefinition":"In the process of being studied; experimental.:A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.:A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C28041:C126108:C12476:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigational","conceptCode":"C28041","definition":"In the process of being studied; experimental.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9251E3-82BE-4715-E053-4EBD850A6E25","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9251E3-82CC-4715-E053-4EBD850A6E25","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7584415","version":"1","preferredName":"Investigational CAR T-Lymphocyte Agent Type Other","preferredDefinition":"free text field to describe other investigational chimeric antigen receptor t-lymphocyte treatment type.","longName":"7584415v1.0","context":"COG","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7584414","version":"1","preferredName":"Chimeric Antigen Receptor Agent Type","preferredDefinition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:Something distinguishable as an identifiable class based on common qualities.","longName":"C126108:C1708:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC07249F-C912-6625-E053-4EBD850A5F2F","latestVersionIndicator":"Yes","beginDate":"2021-02-23","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-23","modifiedBy":"ONEDATA","dateModified":"2021-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC07249F-C923-6625-E053-4EBD850A5F2F","latestVersionIndicator":"Yes","beginDate":"2021-02-23","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-23","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Other, specify:","type":"Preferred Question Text","description":"If Other, specify:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC07249F-C949-6625-E053-4EBD850A5F2F","latestVersionIndicator":"Yes","beginDate":"2021-02-23","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-23","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}